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BCS  British Crime Survey 
CI  confidence intervals 
CSEW  Crime Survey England and Wales 
GBL  gamma-butyrolactone 
GHB  gamma-hydroxybutrate 
LSD  lysergic acid diethylamide 
NMURx  Non-Medical Use of Prescription Drugs 
NUTS  Nomenclature of Territorial Units for Statistics 
RADARS Researched, Abuse, Diversion and Addiction Related Surveillance 
UK  United Kingdom of Great Britain and Northern Ireland 
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Abstract 
Purpose of study: The aim of the study is to describe the prevalence of illicit drug use in England and 
Wales using data from the UK Survey of Non-Medical Use of Prescription Drugs (NMURx) Program, 
and to compare against the well-established Crime Survey England and Wales (CSEW). The rationale 
is that recreational and illicit drug use is common, but the prevalence is difficult to estimate with 
personal interviewing methods. 
Study design: We compared two cross-sectional population surveys (NMURx, n=8,903 and CSEW, 
n=20,685) with data regarding self-reported recreational drug use and demographics. NMURx is an 
online survey using non-probability sampling methodology with pre-set demographical quotas based 
on Census data. CSEW surveys drug use via computer-assisted self-interviewing as part of a 
computer-assisted personal-interviewing crime survey.  
Results: Cannabis was the most frequently used drug regardless of demographics. Prevalence of 
drug use for specific substances was generally higher for males, younger ages, and students. The 
relationship between income and drug misuse is less clear. Self-reported prevalence of drug use in 
the NMURx survey is consistently higher than CSEW (absolute difference 1-3% across substances and 
timescales), and persists after stratification for gender, age, student status and household income. 
Conclusions: The NMURx survey has a broad reach of participants, and a sampling scheme that 
achieves external validity, compared to general population demographics. NMURx’s online format 
allows flexibility in items surveyed, and in response to emerging trends. The self-reported drug use 
in the NMURx cohort is comparable, although slightly higher, than the CSEW estimates.  
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Introduction 
Recreational and illicit drug use is common and can have a significant impact on health.  The 
standardised mortality rate of drug misusers in the United Kingdom (UK) is nearly 5-times that of the 
general population.
1,2
 In addition to individual health consequences, the UK National Crime Agency 
estimates an overall cost of drug use to be £10.7 billion annually, accounting for social, economic 
and reputational impact.
3
  
 
The prevalence of illicit drug use is difficult to estimate, particularly as current methodologies have 
disincentives to report drug use or do not represent the general population, and have limited 
flexibility to adapt to new trends. Not all illicit drug use directly impacts health, or results in 
engagement with drug services, limiting the coverage of database and registry studies. One main 
source of drug use estimates in the UK is the Crime Survey England and Wales (CSEW; formerly 
British Crime Survey (BCS)). The primary purpose of the CSEW survey is to monitor the extent of 
crime in England and Wales, with an optional module regarding drug use. However, face-to-face 
surveys may be limited by the sensitive nature of illicit drug use. Previous studies have combined 
household surveys with drug testing from hair, saliva or urine, revealing that self-reporting 
underestimates the results of laboratory drug testing,
4,5
 although these studies were of a narrower 
selected population with likely higher prevalence of drug use. There have also been recent 
consultations regarding potential changes to CSEW, including removing the drugs module,
6
 
highlighting the importance of a valid alternative methodology for assessing population estimates of 
illicit drug use. 
 
Other drug use prevalence estimates are typically from selected subpopulations. The Global Drug 
Survey, reveals reporting of drug use up to 10-fold higher than CSEW.
7 
However, this self-nominating 
sample is not representative of the general population; being majority male, typically well-educated, 
aged 20-40, with higher night-time economy use. Studies amongst those attending UK sexual health 
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services report drug use prevalence 2- to 10-fold higher than the CSEW.
8,9 
Subpopulation studies are 
crucial in our understanding of recreational drug use in specific contexts, but not easily generalizable 
to the overall population. 
 
This leaves a gap in the literature for a dedicated broad population assessment of illicit drug use. In 
this report, we assessed illicit drug use via a general population online survey, the UK Survey of Non-
Medical Use of Prescription Drugs Program (NMURx). The wide accessibility in an internet-connected 
country such as the UK improves reach, while the anonymous nature of the survey may reduce 
disincentives to report sensitive behaviours like drug use. Utilising a census-based quota for 
demographic variables allows for better representation of the general population. The primary 
objective of this study was to describe the prevalence of illicit drug use in England and Wales using 
the UK NMURx survey. Where applicable, we compared the results to those from the well-
established CSEW. Given the methodological differences between the two surveys, we also critically 
reviewed the strengths and weaknesses of the NMURx survey. 
 
Methods 
Data Sources 
UK Survey of Non-Medical Use of Prescription Drugs Program 
The Researched, Abuse, Diversion and Addiction Related Surveillance (RADARS
®
) System conducts 
drug surveillance through a mosaic of programs at different stages of the drug dependence pathway. 
The RADARS System NMURx Program studies drug use among the general adult population across 
multiple countries, and also collects respondent demographic data.  
 
The NMURx Program collects data through a series of cross-sectional online surveys. The data 
presented relates to the 3
rd
 quarter of 2016 survey (12
th 
August to 1
st
 September 2016). Individuals 
signed up to an online survey panel company are sent e-mail invitations to complete the confidential 
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self-administered survey. The median survey completion time was approximately 10 minutes. 
NMURx uses non-probability quota sampling to provide a distribution of survey respondents 
proportional to populations across regions with an equal gender distribution within each region. The 
sample includes adults aged 16-99. Respondents who complete the survey in less than 2/5 the 
median time (3 minutes and 51 seconds) were excluded. Median time is used as a metric for 
identifying careless responses
10
 as it is expected that participants who finish the questionnaire too 
quickly were unable to provide the required attention to the survey in the short timeframe. 
 
After data collection, post-stratification weights based on strata of UK region, gender, and age 
categories were applied to reflect the demographic distribution of the UK adult population and 
generate population estimates. Weights were calculated using the most recent (2015) population 
estimates by NUTS (Nomenclature of Territorial Units for Statistics) 2 regions provided to Eurostat, 
the statistical office of the European Union.  
 
Respondents were asked about their use of specific drugs (cannabis, cocaine powder, crack cocaine, 
ecstasy, GHB (gamma-hydroxybutrate) / GBL (gamma-butyrolactone), non-pharmaceutical 
amphetamine, non-pharmaceutical fentanyl, heroin, ketamine, and mephedrone) during their 
lifetime, the past year, month, and week. The survey covered the entire UK, but only data from 
England and Wales were compared with CSEW. The NMURx Program was approved by the Colorado 
Multiple Institutional Review Board (Denver, Colorado, United States).  
 
Crime Survey England and Wales (CSEW) 
The CSEW was conducted by Kantar Public on behalf of the Office for National Statistics (ONS). The 
primary purpose of the survey is to monitor crime in England and Wales, and develop crime 
reduction policies. An optional module also surveys drug use (amphetamines, methamphetamines, 
cannabis, cocaine powder, crack cocaine, ecstasy, heroin, LSD/acid, magic mushrooms, non-
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prescribed methadone/physeptone, semeron, tranquilisers, amyl nitrite, anabolic steroids, 
ketamine, mephedrone). The main crime survey invited participants based on a quota of households 
within each Police Force Area. If there was more than one resident within each household, the 
invitee was randomly selected.
11
 The CSEW final data were also weighted to reflect the age and 
gender distribution of the population studied.
12
 Participants aged 60+ were not surveyed with the 
drug use module. The results are publicly available online,
13 
and a further data request was 
submitted to CSEW for prevalence estimates, standard deviation, and number of respondents, to 
derive 95% confidence intervals (95% CIs). 
 
The research question formats for both surveys are shown within Supplementary Table 2. 
 
Analysis 
Analyses for NMURx were conducted in SAS Version 9.4 using the survey procedures to account for 
the weighting scheme, resulting in weighted proportions and 95% CIs. For CSEW data, CIs for 
prevalence estimates were calculated where the upper and lower limits = percentage ± 1.96 * 
standard error of mean * design effect (1.2).
8
 Drug use estimates from the two data sources were 
considered similar if the 95% CIs overlapped. Formal statistical testing was not conducted because 
assumptions about independent and identically distributed samples are likely violated. Demographic 
estimates were compared to values from ONS data.
14-16 
 
Results  
Sample 
The sample sizes for both surveys were large (CSEW n=20,685, NMURx n=8,903). The demographic 
characteristics of the NMURx sample were generally more representative of the general UK 
population for age, gender, region and student status compared to CSEW (Supplementary Table 1). 
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Income statistics were not suitable for direct comparison - neither the NMURx nor CSEW surveys 
specify income type (i.e. gross, net, disposable), while the ONS data specified disposable income.  
 
The response rates for the two surveys were different. For CSEW, 72% of invited individuals 
responded to the main survey, of whom 97% completed the optional drug use module, resulting in a 
70% true response rate.
11
 NMURx, being an online survey, had an unsurprisingly lower response 
rate. The available pool of survey respondents was large (approximately 120,800); 13% (N=15,707) 
opened the survey, of whom 64% (N=10,013) completed the survey. A small number (N=529) of 
responses were excluded due to completion of the survey in a time duration less than 2/5ths of the 
median time. Other exclusions were respondents who were not within the age range, did not agree 
to the confidentiality statement, or were from quotas that were already filled. The resulting 
response rate for NMURx was 8.7%. 
 
Prevalence Estimates  
The most commonly used drug in both surveys was cannabis (Table 1). The ranking of drugs in terms 
of frequency of use was also similar in both surveys; cocaine powder, ecstasy, and amphetamine 
were the next most commonly used. Heroin, GHB/GBL, and non-medical fentanyl had the lowest 
estimated prevalence of lifetime use. Details of self-reported use in shorter timeframes are detailed 
in Table 1. After demographic stratification, drug use in the past year tended to be more prevalent 
for younger ages, males (Table 2), and students (Table 3). For NMURx data, self-reported drug use 
was typically more prevalent with increased income, except for cannabis, being most prevalent 
amongst the <£10k/year income category. This differs from CSEW data where the relationship is less 
clear (Table 4). Cannabis remains the most prevalent drug in all subgroups. 
 
Prevalence estimates of use for all timescales and drugs from the NMURx survey were larger than 
estimates from CSEW (Table 1). The relative difference was more marked for active use categories 
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(i.e. use in last year or month), and for substances with lower overall reporting levels (<3% in CSEW). 
For most categories, the absolute difference between the survey estimates was 1-3%, persisting 
even when stratifying by demographics (Tables 2-4). 
 
Discussion 
The large sample sizes for both surveys provide good statistical power for population estimates. 
Both surveys agreed on the overall patterns of illicit drug use. Cannabis was the most used drug, 
regardless of timeframe, gender, age, student status, or income, reflecting known trends in the UK 
and Europe more widely.
13,17
 Self-reported drug use was higher in males and younger subgroups, 
which is a common finding to drug use estimates.
17-20
 Results from NMURx support the assumption 
made by the CSEW designers that the prevalence of illicit drug use for individuals aged 60+ is low 
(<1%), but not absent. Students were more likely to report illicit drug use; however, these estimates 
can conflate the age difference between students and non-students. The relationship between self-
reported drug use and income were different in the two surveys. While it is not possible to 
conclusively explain this difference, it may be related to differences in survey methodologies.    
 
Prevalence estimates from the NMURx survey were consistently higher than CSEW across 
substances and timescales. These differences were more marked for substances with lower 
prevalence and active use within the last year or month. Two factors may account for these 
differences, potentially indicating strengths of the NMURx survey: 
1. True differences in drug use may exist due to differing sampling strategies, where the 
NMURx cohort better reflects national census estimates than CSEW (Supplementary Table 
1). NMURx targets individuals willing to fill out internet surveys for modest compensation, 
while CSEW targets households within police enforcement areas using postal letters. 
Additionally, CSEW does not include communal residences (such as university dormitories), 
which could contribute to discrepancies. Neither survey effectively targets prison 
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populations or the homeless. An analysis of CSEW determined these exclusions have “little 
impact on the overall estimates of the prevalence of victimisation”,
21
 but this considers the 
CSEW main focus on crime, and not the impact on drug use estimation.  
2. Differences in survey methodologies may contribute to differences in willingness to report 
drug use, supported by the finding that differences persist after demographic stratification 
(Table 2-4). NMURx is an anonymous online survey that solely focuses on drug use. In 
contrast, CSEW drug use data are obtained at the end of a government-associated core 
interview survey on crime as a non-compulsory module. The core interview is conducted as 
a ‘computer-assisted personal interview’, with the interviewer asking questions from and 
inputting answers into a computer, surveying experiences of crime victimisation and 
perceptions of crime-related issues. Occasionally, the survey prompts “drugs” as a potential 
contributor to crime. The CSEW drugs module is subsequently completed anonymously with 
computer-assistance ‘computer-assisted self-interview’, but still in the presence of an 
interviewer. The importance of question structure, context and preceding questions have 
been shown in CSEW methodology reports to influence self-reporting of intimate personal 
violence and attitudes towards the police and criminal justice system.
22,23
 It is possible that 
the structure of CSEW, being linked to questions on crime influences reporting of illicit drug 
use. Furthermore, CSEW allows “Don’t want to answer” responses. This allows respondents 
to mask potential drug use with a non-committal answer that is not recorded as drug use. 
This option is not present with NMURx. A further difference is that NMURx formats the 
question in a table where all options are available, whereas CSEW asks sequential questions. 
Detailed differences between the surveys are outlined in Supplementary Table 2. 
 
The main limitations to the NMURx survey are selection and non-response biases inherent in survey 
panels. Survey panels are self-selected, with potential for non-representative samples. However, 
NMURx utilizes pre-set quotas based on Census data and post-stratification weighting to represent 
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the general UK adult population. There is also potential for non-response bias, with a response rate 
of 8.7%. Although there are no clear disincentives to participating in this comparatively short, 
anonymous, online survey, it cannot be determined whether non-respondents differ in 
characteristics to respondents. However, respondents do not know the topic of the survey until they 
agree to the confidentiality statement, reducing such bias. Concerns of coverage bias are small, as 
internet coverage is extensive throughout England and Wales. Although the 16-19-year old group is 
under-represented in the NMURx survey, it is closer than CSEW to the general population (16-19 age 
group in Eurostat: 8.22%, in NMURx: 5.79%, and in CSEW: 4.19%). Exclusion bias, if present, is likely 
to be a small effect. A small number (n=529) of respondents had their surveys removed due to 
survey completion times faster than a pre-set industry standard cut-off. At one extreme, those who 
finish the survey quickly could all respond they have not used any drug in this analysis. With this 
small number, even if they were included as never-users for all drugs surveyed, it will decrease the 
point prevalence estimates by a small amount. The exclusion of this small number of fast responders 
would neither significantly bias the NMURx findings upwards nor would this change the overall 
conclusions of the study. 
 
A major advantage of the short and succinct online format of the NMURx survey is the extensive 
analysis across multiple drugs. This is exemplified with the data obtained on GHB/GBL and non-
prescribed fentanyl use, together with the extended age range covered. The survey could be 
expanded to explore other substance uses, or additional demographic data to allow for better 
stratification and further external validity in comparison to the general population. Additions can be 
quickly implemented in this flexible online format. Some additions have already been implemented, 
including ethnicity, marital status, highest education achieved, and alcohol consumption.  
 
In summary, both CSEW and NMURx demonstrate that illicit drug use is common in England and 
Wales, self-reported drug use is higher in younger ages, males, and students, and cannabis use is the 
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most prevalent regardless of demographics. Prevalence estimates from the NMURx survey were 
consistently higher than, but comparable to, those of CSEW. These differences could be related to 
the population studied, where NMURx better reflects the general population, or the differences 
between an anonymous online survey (NMURx) against a government-associated interview survey 
on crime (CSEW). The NMURx program can provide timely, national estimates and is specifically 
designed to measure drug use. Whilst online survey panels have limitations, this study is evidence 
for external validity of the NMURx survey through illustration of similarities to the nationally 
accepted standard survey for illicit drug use, CSEW. This indicates that an anonymous online general 
population survey could be a method of assessing drug use across the general population, as 
opposed to subgroups, and NMURx can be a valuable data source to monitor trends and conduct 
research on drug use in the UK. 
 
 “What is already known on the subject”  
- Illicit drug use is common, and cannabis use is most prevalent 
- Demographical characteristics such as younger age, male and students also have a higher 
prevalence of ongoing (within last year) drug use 
- General population surveys can underreport true rates of illicit drug use 
 
Study’s main messages 
- A short cross-sectional online survey, with non-probability sampling methodology and pre-set 
demographical quotas based on Census data, focusing on illicit drug use is feasible and obtains a 
large dataset the demographics that reflect the overall UK adult population. 
- This online survey finds prevalence of illicit drug use that is similar, but consistently higher, than 
previously established household surveys. This may potentially reflect the strengths of the 
online survey with its more representative cohort, or its anonymous, online and focused survey 
methodology and faster turnaround time from survey launch to available results. 
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- Like all online surveys, there are limitations particularly regarding response rates and potential 
non-response bias. 
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Research Questions 
- Are there similar discrepancies in drug misuse reporting with regards to face-to-face vs. online 
surveys in different countries? 
- Why does the relationship between self-reported drug use and income differ between the two 
survey methodologies? 
- Is the use of online surveys an appropriate and cost-effective alternative method for long-term 
assessment of trends in drug misuse? 
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Tables (with legends) 
 Lifetime Use Last Year Use Last Month Use 
NMURx CSEW NMURx CSEW NMURx CSEW 
Cannabis 31.36%  
(30.19 -  32.54) 
29.42%  
(28.68 - 30.16) 
8.81%  
(8.06 - 9.55) 
6.47%  
(6.07 - 6.87) 
6.24%  
(5.61 - 6.88) 
3.24%  
(2.96 - 3.53) 
Cocaine Powder 13.64%  
(12.78 - 14.51) 
9.65%  
(9.17 - 10.13) 
4.96%  
(4.41 - 5.51) 
2.21%  
(1.97 - 2.45) 
2.82%  
(2.41 - 3.23) 
0.84%  
(0.69 - 0.99) 
Crack Cocaine 4.63%  
(4.11 - 5.14) 
1.00%  
(0.84 - 1.16) 
3.06%  
(2.64 - 3.48) 
0.09%  
(0.04 - 0.14) 
2.26%  
(1.90 - 2.63) 
0.05%  
(0.01 - 0.08) 
Ecstasy 13.45%  
(12.59 - 14.32) 
9.39%  
(8.92 - 9.86) 
4.45%  
(3.93 - 4.98) 
1.50%  
(1.30 - 1.70) 
2.46%  
(2.07 - 2.84) 
0.39%  
(0.29 - 0.50) 
Amphetamine 12.31%  
(11.50 - 13.12) 
10.12%  
(9.63 - 10.61) 
3.27%  
(2.83 - 3.71) 
0.60%  
(0.48 - 0.73) 
2.23%  
(1.87 - 2.60) 
0.16%  
(0.10 - 0.23) 
Ketamine 6.18%  
(5.57 - 6.79) 
2.37%  
(2.13 - 2.62) 
2.65%  
(2.25 - 3.04) 
0.29%  
(0.20 - 0.37) 
1.64%  
(1.33 - 1.96) 
0.06%  
(0.02 - 0.11) 
Mephedrone 4.58%  
(4.06 - 5.11) 
2.01%  
(1.78 - 2.24) 
2.64%  
(2.24 - 3.3) 
0.27%  
(0.19 - 0.36) 
1.79%  
(1.45 - 2.12) 
0.11%  
(0.06 - 0.16) 
Heroin 4.08%  0.58%  2.63%  0.08%  1.77%  0.05%  
Page 19 of 30
https://mc.manuscriptcentral.com/postgradmed
Postgraduate Medical Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
(3.59 - 4.57) (0.46 - 0.70) (2.23 - 3.02) (0.03 - 0.13) (1.45 - 2.09) (0.01 - 0.08) 
GHB/GBL 3.95%  
(3.47 - 4.43) 
N/A 2.39%  
(2.01 - 2.76) 
N/A 1.68%  
(1.37 - 1.99) 
N/A 
Non-medicinal fentanyl 3.31%  
(2.87 - 3.74) 
N/A 2.44%  
(2.06 - 2.82) 
N/A 1.74%  
(1.42 - 2.06) 
N/A 
Table 1: Estimated prevalence of recreational drug use in CSEW and NMURx surveys for those aged 16-59 in England and Wales - listed by lifetime use, use in last year and 
use in last month.  
95% CI in parentheses. N/A Data not collected by CSEW. 
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 Males Females 
16-24 25-59 60+ 16-24 25-59 60+ 
NMURx CSEW NMURx CSEW NMURx CSEW NMURx CSEW NMURx CSEW NMURx CSEW 
Cannabis 17.16% 
(13.26 - 
21.05) 
19.94% 
(17.11 - 
22.77) 
9.26% 
(8.14 - 
10.37) 
6.57% 
(5.93 - 
7.21) 
0.78% 
(0.32 - 
1.24) 
N/A 14.05% 
(10.91 - 
17.19) 
11.52% 
(9.44 - 
13.61) 
5.02% 
(4.23 - 
5.81) 
2.11% 
(1.77 - 
2.44) 
0.26% 
(0.05 - 
0.46) 
N/A 
Cocaine Powder 7.39% 
(4.85 - 
9.92) 
5.91% 
(4.25 - 
7.56) 
6.12% 
(5.21 - 
7.03) 
2.65% 
(2.24 - 
3.06) 
0.11% 
(0.00 - 
0.27) 
N/A 6.61% 
(4.42 - 
8.81) 
2.92% 
(1.82 - 
4.01) 
2.81% 
(2.21 - 
3.40) 
0.75% 
(0.55 - 
0.95) 
0.06% 
(0.00 - 
0.17) 
N/A 
Crack Cocaine 5.15% 
(3.15 - 
7.15) 
N/A 3.68% 
(2.99 - 
4.37) 
N/A 0.00% N/A 3.45% 
(1.87 -
5.03) 
N/A 1.83% 
(1.35 -
2.31) 
N/A 0.00% N/A 
Ecstasy 7.87% 
(5.25 - 
10.49) 
6.06% 
(4.39 - 
7.74) 
4.61% 
(3.82 - 
5.39) 
1.24% 
(0.95 - 
1.52) 
0.04% 
(0.00 - 
0.13) 
N/A 8.66% 
(6.14 - 
11.18) 
2.93% 
(1.83 - 
4.03) 
2.44% 
(1.89 - 
2.99) 
0.36% 
(0.22 - 
0.50) 
0.00% N/A 
Amphetamine 5.10% 
(3.07 - 
7.13) 
1.60% 
(0.72 - 
2.48) 
3.74% 
(3.03 - 
4.44) 
0.62% 
(0.42 - 
0.82) 
0.00% N/A 4.15% 
(2.40 - 
5.90) 
0.63% 
(0.11 - 
1.14) 
2.15% 
(1.63 - 
2.67) 
0.34% 
(0.21 - 
0.48) 
0.00% N/A 
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Ketamine 4.08% 
(2.26 - 
5.91) 
1.65% 
(0.76 - 
2.55) 
3.14% 
(2.51 - 
3.78) 
0.19% 
(0.08 - 
0.31) 
0.00% N/A 3.44% 
(1.82 - 
5.05) 
0.30% 
(0.00 - 
0.66) 
1.62% 
(1.17 - 
2.07) 
0.05% 
(0.00 - 
0.11) 
0.06% 
(0.00 -
0.17) 
N/A 
Mephedrone 4.39% 
(2.48 - 
6.31) 
1.36% 
(0.55 - 
2.17) 
3.32% 
(2.66 - 
3.98) 
0.18% 
(0.07 - 
0.29) 
0.00% N/A 2.56% 
(1.18 - 
3.95) 
0.50% 
(0.04 - 
0.95) 
1.54% 
(1.10 - 
1.98) 
0.05% 
(0.00 - 
0.10) 
0.00% N/A 
Heroin 4.21% 
(2.33 - 
6.10) 
N/A 3.25% 
(2.60 - 
3.89) 
N/A 0.00% N/A 3.10% 
(1.59 - 
4.60) 
N/A 1.51% 
(1.07 - 
1.94) 
N/A 0.00% N/A 
GHB/GBL 4.26% 
(2.41 - 
6.11) 
N/A 2.88% 
(2.27 - 
3.49) 
N/A 0.00% N/A 1.86% 
(0.71 - 
3.02) 
N/A 1.56% 
(1.11 - 
2.00) 
N/A 0.00% N/A 
Non-medicinal 
fentanyl 
3.90% 
(2.11 - 
5.70) 
N/A 3.08% 
(2.45 - 
3.70) 
N/A 0.13% 
(0.00 - 
0.33) 
N/A 2.30% 
(1.01 - 
3.60) 
N/A 1.48% 
(1.05 - 
1.91) 
N/A 0.00% N/A 
Table 2: Estimated prevalence of recreational drug use in the past year in both CSEW and NMURx surveys for England and Wales - stratified by gender x age 
95% CI in parentheses. N/A Data not collected by CSEW. 
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Student Non-student 
NMURx  CSEW  NMURx  CSEW 
#
 
Cannabis 14.76% (12.07 - 17.45) 14.57% (11.44 - 17.71) 7.81% (7.06 - 8.55) 6.19% (5.80 - 6.59) 
Cocaine Powder 8.35% (6.44 - 10.26) 3.45% (1.83 - 5.06) 4.39% (3.83 - 4.94) 2.17% (1.93 - 2.41) 
Crack Cocaine 6.71% (5.02 - 8.40) N/A 2.45% (2.05 - 2.85) N/A 
Ecstasy 11.06% (8.77 - 13.35) 5.02% (3.08 - 6.95) 3.34% (2.87 - 3.82) 1.38% (1.19 - 1.57) 
Amphetamine 7.46% (5.67 - 9.25) 2.10% (0.83 - 3.37) 2.57% (2.15 - 2.98) 0.60% (0.47 - 0.72) 
Ketamine 6.01% (4.40 - 7.63) 0.99% (0.12 - 1.87) 2.08% (1.71 - 2.46) 0.27% (0.18 - 0.35) 
Mephedrone 6.46% (4.78 - 8.14) 1.21% (0.24 - 2.18) 1.99% (1.63 - 2.36) 0.24% (0.16 - 0.32) 
Heroin 6.23% (4.59 - 7.88) N/A 2.02% (1.65 - 2.38) N/A 
GHB/GBL 5.17% (3.70 - 6.65) N/A 1.92% (1.56 - 2.27) N/A 
Non-medicinal fentanyl 5.71% (4.17 - 7.26) N/A 1.89% (1.53 - 2.24) N/A 
Table 3: Estimated prevalence of recreational drug use in the past year in both CSEW and NMURx surveys for those aged 16-59 in England and Wales - stratified by student 
status 
#
 CSEW “non-student” subgroup is not a defined CSEW grouping, and was calculated by subtracting the reported student subgroup from the overall sample population 
95% CI in parentheses. N/A Data not collected by CSEW. 
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 <£10k £10k-£20k £20k-£30k £30k-£50k >£50k 
NMURx CSEW NMURx CSEW NMURx CSEW NMURx CSEW NMURx CSEW 
Cannabis 13.13% 
(10.07 - 
16.19) 
9.67%  
(7.97 - 
11.37) 
9.42%  
(7.55 - 
11.28) 
7.47%  
(6.35 - 8.59) 
9.04%  
(7.28 - 
10.80) 
6.02%  
(5.00 - 7.04) 
7.67%  
(6.38 - 8.97) 
4.96%  
(4.23 - 5.69) 
9.13%  
(7.47 - 
10.79) 
6.06%  
(5.29 - 6.84) 
Cocaine 
Powder 
2.87%  
(1.50 - 4.25) 
2.62%  
(1.70 - 3.54) 
4.89%  
(3.51 - 6.28) 
1.90%  
(1.32 - 2.48) 
3.60%  
(2.49 - 4.70) 
1.27%  
(0.79 - 1.75) 
5.96%  
(4.82 - 7.10) 
1.78%  
(1.33 - 2.22) 
7.39%  
(5.96 - 8.83) 
3.03%  
(2.47 - 3.59) 
Crack Cocaine 0.83%  
(0.10 - 1.56) 
N/A 
2.20%  
(1.29 - 3.10) 
N/A 
1.98%  
(1.15 - 2.81) 
N/A 
3.64%  
(2.77 - 4.51) 
N/A 
6.29%  
(4.98 - 7.60) 
N/A 
Ecstasy 3.17%  
(1.52 - 4.82) 
2.06%  
(1.24 - 2.87) 
3.96%  
(2.73 - 5.18) 
1.02%  
(0.59 - 1.44) 
2.74%  
(1.75 - 3.74) 
0.63%  
(0.29 - 0.97) 
4.89%  
(3.87 - 5.91) 
0.93%  
(0.61 - 1.25) 
7.67%  
(6.17 - 9.16) 
2.20%  
(1.72 - 2.68) 
Amphetamine 1.37%  
(0.42 - 2.32) 
1.06%  
(0.47 - 1.65) 
3.12%  
(2.06 - 4.19) 
1.10%  
(0.66 - 1.55) 
1.93%  
(1.11 - 2.76) 
0.33%  
(0.09 - 0.58) 
3.77%  
(2.88 - 4.65) 
0.55%  
(0.30 - 0.80) 
5.99%  
(4.71 - 7.28) 
0.50%  
(0.27 - 0.73) 
Ketamine 0.64%  
(0.01 - 1.28) 
0.22%  
(0.00 - 0.49) 
1.97%  
(1.10 - 2.83) 
0.28%  
(0.05 - 0.50) 
1.37%  
(0.71 - 2.03) 
0.28%  
(0.06 - 0.51) 
3.35%  
(2.50 - 4.19) 
0.13%  
(0.01 - 0.25) 
5.18%  
(3.99 - 6.37) 
0.39%  
(0.19 - 0.59) 
Mephedrone 1.14%  
(0.29 - 1.99) 
0.18%  
(0.00 - 0.41) 
1.94%  
(1.09 - 2.80) 
0.27%  
(0.05 - 0.50) 
1.85%  
(1.04 - 2.66) 
0.17%  
(0.00 - 0.34) 
3.23%  
(2.41 - 4.05) 
0.24%  
(0.08 - 0.41) 
4.79%  
(3.65 - 5.94) 
0.31%  
(0.13 - 0.49) 
Heroin 1.13%  N/A 1.86%  N/A 1.84%  N/A 3.09%  N/A 4.95%  N/A 
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(0.29 - 1.98) (1.02 - 2.71) (1.03 - 2.64) (2.29 - 3.89) (3.79 - 6.11) 
GHB/GBL 0.69%  
(0.01 - 1.37) 
N/A 1.21%  
(0.55 - 1.88) 
N/A 1.80%  
(1.01 - 2.59) 
N/A 3.10%  
(2.29 - 3.91) 
N/A 4.69%  
(3.56 - 5.81) 
N/A 
Non-medicinal 
fentanyl 
0.83%  
(0.10 - 1.56) 
N/A 1.75%  
(0.94 - 2.57) 
N/A 1.62%  
(0.87 - 2.37) 
N/A 3.16%  
(2.35 - 3.96) 
N/A 4.50%  
(3.39 - 5.61) 
N/A 
Table 4: Estimated prevalence of recreational drug use in the past year in both CSEW and NMURx surveys for those aged 16-59 in England and Wales - stratified by 
household income 
95% CI in parentheses. N/A Data not collected by CSEW.
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Supplementary tables 
 
 NMURx CSEW General population [REF] 
Unweighted N  
Weighted N 
8,903 
37.4 million 
20,685 
32.8 million 
33,245,355  [14] 
Sex: Female 51.13% (49.99 - 52.28) 54.87% (54.20 – 55.54) 50.02%  [14] 
Age category (% 
calculated as 
proportion of those 
aged 16-59) 
16-19 5.79% (5.07 - 6.52) 4.19% (3.92 – 4.46) 8.22% [14] 
20-24 14.02% (12.97 - 15.06) 7.28% (6.93 – 7.63) 11.36% 
25-29 10.40% (9.66 - 11.14) 10.52% (10.11 – 10.93) 11.80% 
30-34 13.19% (12.36 - 14.01) 12.37% (11.92 – 12.82) 11.67% 
35-44 22.46% (21.45 - 23.48) 25.27% (24.68 – 25.86) 22.29% 
45-54 24.37% (23.33 - 25.41) 28.02% (27.41 – 28.62) 24.28% 
55-59 9.77% (9.18 - 10.36) 12.34% (11.89 – 12.79) 10.37%  
Residential region England (excluding London) 79.87% (78.95 - 80.79) 81.14% (80.71 – 81.57) 78.22% [14] 
London 14.68% (13.88 - 15.47) 11.38% (10.84 – 11.90) 16.61% 
Wales 5.46% (4.90 - 6.01) 7.49% (7.14 – 7.84) 5.18% 
Household income  <£10000 8.52% (7.85 - 9.19) 7.91% (7.55 – 8.23) No directly comparable [15] 
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£10000-£19999 8.52% (7.85 - 9.19) 14.53% (14.05 – 15.01) dataset.  
Bottom 1
st
 decile <£13,586, 
bottom 3
rd
 decile <£20,007, 
bottom 6
th
 decile <£30,425, top 
decile >£53,448 
£20000-£29999 19.46% (18.56 - 20.36) 14.51% (14.03 – 14.99) 
£30000-£49999 26.56% (25.57 - 27.55) 23.27% (22.70 – 23.85) 
>£50000 16.00% (15.21 - 16.80) 24.92% (24.33 – 25.51) 
 No information provided 8.43% (7.75 - 9.12) 14.86% (14.38 – 15.35) 
Students 10.37% (9.62 - 11.12) 3.36% (2.89 – 3.83) Crude estimate 7-8% *  [16] 
Supplementary Table 1: Demographical data for CSEW and NMURx respondents 
* General population data for students obtained from UK labour market Feb 2017 [16], based on overall UK seasonally adjusted (October to December 2016) estimates; 
there were no readily available figures based on England and Wales alone. 
95% CI in parentheses. Grouping by residential region was limited by data from NMURx. Data from CSEW includes further stratification of other regions within England. 
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 NMURx CSEW 
Format Online Computer-assisted self-interviewing module, in 
presence of interviewer from main survey 
Invitation 
method 
E-mail Leaflet via post, with follow up personal visit to 
arrange interview 
Sampling  Uses pre-set gender and region quotas based 
on Census data  
Postcode data is available, so further 
stratification is possible 
Cluster design - by setting minimum of 
households surveyed (650) in each of the 42 
Police Force Area [Ref 11] 
A whole household is selected, and if more than 
one resident aged over 16 in household, 
participant is chosen at random 
Context  Isolated survey regarding drug use only Drug use module completed at the end of the 
face-to-face interview that mainly covers 
questions on experiences of crime victimisation 
and perceptions of crime-related issues 
Duration of 
survey  
3Q16 Median: 9 minutes 37 seconds 
3Q16 Average: 13 minutes 49 seconds 
Mean duration of core interview 2014-15 was  
47 minutes 
(duration dependent on number of 
Victimisation Modules completed: 20% took 
over 60 minutes) 
 
Mean duration of CASI modules (including drug 
misuse) 2014-15 was 14.4 minutes [Ref 24] 
 
Note: Respondents would have had to complete 
both sections to have relevant drugs misuse 
data 
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Question 
layout  
Table format. 
9 drugs (can include street name examples). 
Options (single tick): 
• No 
• Yes, in the last week 
• Yes, in the last 30 days 
• Yes, in the last 12 years 
• Yes, during my lifetime 
 
Have you [EVER] taken ... [including street 
names] [in time period]? 
1. Yes 
2. No 
3. Never heard of it 
4. Don't want to answer 
Separate questions for lifetime use, last year 
and last month (in that order) 
[Ref 25] 
Population 
(see Table 2) 
Registered participants from an online survey 
panel 
Estimated compensation ~ £3 per 
respondent 
Households within Police Force Areas, and does 
include group residences or other institutions 
[Ref 11] 
No financial compensation for respondent 
Weighting  Post-stratification weighting based on UK 
Census age, gender, and region 
Two step weighting process: 
Step 1 - Raw data weighted to compensate for 
unequal probabilities of selection involved in 
the sample design (by commercial contractor) 
Step 2 - Calibration weighting is used to adjust 
for differential non-response - by geography (by 
Office of National Statistics / Home Office) 
Response 
rate 
8.4% ~70% 
Supplementary Table 2: Comparisons between CSEW and NMURx surveys 
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